Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?
At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
A gene called MET codes for a protein called MET [...]
In a study presented during the 2020 American Society of [...]
Overall survival results from a study with a combination of [...]
Results from a first-in-human phase 1 study of savolitinib in [...]
Results from this trial for papillary renal cell carcinoma (RCC) [...]
Despite significant improvements in the treatment outcomes of clear cell [...]
Chi-Med (Hutchinson Pharma), a Hong Kong-based biotechnology company, and AstraZeneca [...]
This video interview summarises treatments in development for papillary renal [...]
Papillary renal cell carcinoma (pRCC) is the second most common [...]